NIT084A
Illness / Medicines
Includes diseases for which entitlements to reimbursement for medicines commenced, were withdrawn or existed during the year and existing entitlements at the end of the year.
Reimbursement is granted in the case of
On 1January 2011, entitlement to special refunds for dyslipidaemia associated with chronic coronary heart disease (213) was included in the entitlement to special refunds for chronic coronary heart disease (206). After this change, all those who are entitled to special refunds for medicinal care related to chronic coronary heart disease (206) have received special refunds also for medicines entitling to special refund for treatment of dyslipidaemia associated with chronic coronary heart disease. Previously granted separate entitlements to special refunds in the case of dyslipidaemia associated with chronic coronary heart disease (213) will, however, still continue to be in effect.
On 1 January 2017, diabetes medications, with the exception of insulins, were transferred to the lower special refund category. The following new reimbursement entitlements were created for them: ‘215 Diabetes, non-insulin-treated’, and ‘285 Exenatide and liraglutide’. The reimbursement entitlement ‘Diabetes’ (103) was changed to ‘103 Diabetes, insulin-treated’. The qualifying conditions for reimbursement entitlements 102 and 215 remain the same.
Data available from 1986.
Updated annually in February.
Kela – The Social Insurance Institution of Finland
Additional information on entitlement to special reimbursement for medicines is available at www.kela.fi under Our Services » Sickness » Medicine expenses » Special reimbursement and at the same address under About Kela » Statistics » Statistics by topic » Reimbursement entitlements in respect of medicines.
Kela, Statistical Information Service
Email: tilastot@kela.fi